Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients.

ABSTRACT:

Background

Cystic fibrosis (CF) lung transplant (LT) recipients may warrant treatment with elexacaftor/tezacaftor/ivacaftor (ETI) to improve extrapulmonary manifestations of CF. Our objectives were to identify reasons for prescribing ETI after LT and evaluate changes in body mass index (BMI), hemoglobin A1c, hemoglobin, and liver enzymes.

Methods

This was an electronic health record-based cohort study, October 2019-September 2020, at 14 CF LT Consortium sites in North America. The study included CF LT recipients prescribed ETI after transplant. Differences in BMI, A1c, and hemoglobin were assessed with paired t-tests.

Results

There were 94 patients prescribed ETI; indications included sinus disease (68%), GI symptoms (39%), or low BMI (19%). Prescriptions were written

SUBMITTER: Ramos KJ 

PROVIDER: S-EPMC9509406 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature